The value of in vitro diagnostic testing in medical practice: A status report

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Rohr, Ulrich Peter ^a   Binder, Carmen ^b   Dieterle, Thomas ^c   Giusti, Francesco ^d   Messina, Carlo Guiseppe Mario ^e   Toerien, Eduard ^f   Moch, Holger ^b   Hendrikschäfer, Hans ^e,g  

^a Roche Diagnostics   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Kantonsspital Liestal   (Switzerland)

^d EORTC DATA CENTER   (Belgium)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY OF PRETORIA   (South Africa)

^g JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AWARENESS; CARDIOLOGIST; CELL CULTURE MONITORING; CLINICAL DECISION MAKING; CONSENSUS DEVELOPMENT; DIAGNOSIS; DOCTOR PATIENT RELATION; GERMANY; HEALTH CARE COST; HUMAN; IN VITRO STUDY; MARKET; MEDICAL PRACTICE; MONITORING; ONCOLOGIST; PATIENT CARE; PERCEPTION; ALGORITHM; CARDIOLOGY; CLINICAL DECISION SUPPORT SYSTEM; CLINICAL PRACTICE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; ECONOMICS; INFORMATION PROCESSING; ONCOLOGY; QUESTIONNAIRE; UNITED STATES; UTILIZATION;

ALGORITHMS; CARDIOLOGY; COST-BENEFIT ANALYSIS; DATA COLLECTION; DECISION SUPPORT SYSTEMS, CLINICAL; DIAGNOSTIC TESTS, ROUTINE; GERMANY; HEALTH CARE COSTS; HUMANS; MEDICAL ONCOLOGY; PRACTICE PATTERNS, PHYSICIANS'; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84961839172     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149856     Document Type: Article

References (54)

1. Raman G, Avendano E, Chen M. Update on Emerging Genetic Tests Currently Available for Clinical Use in Common Cancers, in Technology Assessment Report. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
2. Billings PR. Three barriers to innovative diagnostics. Nat Biotechnol. 2006;24:917-918. PMID: 16900129
3. Blendon RJ, Schoen C, Des Roches CM, Osborn R, Zapert K, Raleigh E. Confronting competing demands to improve quality: a five-country hospital survey. Health Aff (Millwood). 2004;23:119-135.
4. Wilke MH, Schenker M, Hoffmann G. Detection and documentation of DRG-relevant comorbidities using laboratory tests. Aust Health Rev. 2002;25:152-160. PMID: 12136557
5. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364:249-256. PMID: 15262102
6. Liu S, Semenciw R, Probert A, Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer. 2001;11:24-31. PMID: 11285030
7. Levi F, Lucchini F, Negri E, Franceschi S, La Vecchia C. Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer. 2000;36:2266-2271. PMID: 11072218
8. Mignogna MD, Fedele S, Lo Russo L, Ruoppo E, Lo Muzio L. Costs and effectiveness in the care of patients with oral and pharyngeal cancer: analysis of a paradox. Eur J Cancer Prev. 2002;11:205-208. PMID: 12131652
9. Cressman S, Lam S, Tammemagi MC, Evans WK, Leighl NB, Regier DA, et al. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol. 2014;9:1449-1458. doi: 10.1097/JTO.0000000000000283 PMID: 25105438
10. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637-650. doi: 10.1038/modpathol.2011.198 PMID: 22222640
11. US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools); 2015 [cited October 1, 2015]. Available: http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htm.
12. US Food and Drug Administration. Paving the way for personalized medicine: FDA's role in a new era of medical product development; 2013 [cited October 1, 2015]. Available: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf. Accessed 1 October 2015.
13. Saltz L. 2015 ASCO Annual Meeting: Perspectives on Value-Plenary Session Including the Science of Oncology Award and Lecture.. 2015: Chicago.
14. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. American Society of Clinical Oncology Statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563-2677. doi: 10.1200/JCO.2015.61.6706 PMID: 26101248
15. Porter ME. What is value in health care? N Engl J Med. 2010;363:2477-2481. doi: 10.1056/NEJMp1011024 PMID: 21142528
16. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nded. Oxford: Oxford University Press; 1997.
17. Porter ME, Teisberg EO. Redefining competition in healthcare. HarvBus Rev. 2004;82:64-76, 136.
18. Bissell MG. Laboratory-related measures of patient outcomes: An introduction. Washington, DC, US: AACC Press; 2000.
19. Sarata AK, Johnson JA. Regulation of clinical tests: In vitro diagnostic (IVD) devices, laboratory developed tests (LDTs), and genetic tests. Washington, DC, US: Congressional Research Service; 2014. Available: https://www.fas.org/sgp/crs/misc/R43438.pdf.
20. Smith KM, Kates JA. Regulatory hurdles in bringing an in vitro diagnostic device to market. ClinChem. 1996;42:1556-1557. PMID: 8787729
21. Miller I, Ashton-Chess J, Spolders H, Fert V, Ferrara J, Kroll W, et al. Market access challenges in the EU for high medical value diagnostic tests. Personalized Medicine. 2011;8:137-148.
22. Anonychuk A, Beastall G, Shorter S, Kloss-Wolf R, Neumann P. A framework for assessing the value of laboratory diagnostics. Healthc Manage Forum. 2012;25(3 Suppl):S4-S11.
23. Price CP. Evidence-based laboratory medicine: supporting decision-making. Clin Chem. 2000;46:1041-1050. PMID: 10926881
24. Lazar EJ, Fleischut P, Regan BK. Quality measurement in healthcare. Annu Rev Med. 2013;64:485-496. doi: 10.1146/annurev-med-061511-135544 PMID: 23190148
25. Durtschi A, Julicher P. Assessing the value of cardiac biomarkers: going beyond diagnostic accuracy? Future Cardiol. 2014;10:367-380. doi: 10.2217/fca.14.26 PMID: 24976474
26. The Lewin Group, Inc. The value of diagnostics innovation, adoption and diffusion into health care; 2005. Available: http://www.lewin.com/~/media/Lewin/Site Sections/Publications/ValueofDiagnostics.pdf.
27. Centers for Medicare & Medicaid Services. National health expenditure data (research, statistics, data and systems). Available: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html.
28. st Annual J. P. Morgan Healthcare Conference January 9, 2013. Available: http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-presentations.
29. Health expenditures in Germany as share of GDP and in millions of Euro (absolute and per inhabitant). Health expenditure, time series. Available: http://www.gbe-bund.de/gbe10/trecherche.prc them rech? tk=19200&tk2=19300&p uid=gast&p aid=71688746&p sprache=E&cnt ut=10&ut=19310.
30. Organisation for Economic Co-operation and Development. Country note: How does health spending in Germany compare? OECD Health Statistics; 2015. Available: http://www.oecd.org/els/healthsystems/Country-Note-GERMANY-OECD-Health-Statistics-2015.pdf.
31. World Health Organization. WHO global health expenduture atlas. Available: http://apps.who.int/nha/atlasfinal.pdf.
32. Busse R, Riesberg A. Health care systems in transition. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2014.
33. Organisation for Economic Co-operation and Development. Pharmaceutical spending (indicator). Available: https://data.oecd.org/healthres/pharmaceutical-spending.htm.
34. Blank PR, et al. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res. 2011;17:6338-6346. doi: 10.1158/1078-0432. CCR-10-2267 PMID: 21807639
35. Blank PR, Schwenkglenks M, Moch H, Szucs TD. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat. 2010;124:497-507. doi: 10.1007/s10549-010-0862-7 PMID: 20364309
36. Arnett DK, Claas SA, Glaser SP. Pharmacogenetics of antihypertensive treatment. Vascular Pharmacology 2006;44:107-118. PMID: 16356784
37. Stankovic A. The role of in vitro diagnostic companies in reducing laboratory error. Clin Chem Lab Med 2007;45:781-788. PMID: 17579532
38. Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clinical Chemical Laboratory Medicine. Band 44, Heft 6, Seiten 750-759, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, doi: 10.1515/CCLM.2006.123, May 2006.
39. Plebani M. The detection and prevention of errors in laboratory medicine. Ann Clin Biochem 2010;47:101-10. doi: 10.1258/acb.2009.009222 PMID: 19952034
40. Lippi G, Plebani M, Graber ML. Building a bridge to safe diagnosis in healthcare. The role of the clinical laboratory. ClinChem Lab Med. 2015 Dec2. pii:/j/cclm.ahead-of-print/cclm-2015-1135/cclm-2015-1135.xml. [Epub ahead of print]).
41. Epner PL, Gans JE, Graber ML. When diagnostic testing leads to harm: a new outcomes-based approach for laboratory medicine. BMJ Qual Saf 2013;22(Suppl 2): ii6-ii10. doi: 10.1136/bmjqs-2012-001621 PMID: 23955467
42. Lewandrowski K. Managing utilization of new diagnostic tests. Clin Leadersh Manag Rev. 2003;17:318-324. PMID: 14692073
43. Zhi M, Ding EL, Theisen-Toupal J, Whelan J, Arnaout R. The landscape of inappropriate laboratory testing: a 15-year meta-analysis. PLoS One 2013;8(11):e78962. doi: 10.1371/journal.pone.0078962 PMID: 24260139
44. American Board of Internal Medicine. Choosing Wisely; [cited August 19, 2015]. Available: http://www.choosingwisely.org/.
45. Swiss Society of General Internal Medicine. Smarter Medicine; [cited August 19, 2015]. Available: www.smartermedicine.ch.
46. Sinaiko AD, Rosenthal MB. Increased price transparency in health care-challenges and potential effects. N Engl J Med. 2011;364:891-894. doi: 10.1056/NEJMp1100041 PMID: 21388306
47. Carlson J, Dachs RJ. Family medicine residents remain unaware of hospital charges for diagnostic testing. FamMed. 2015;47:466-469. PMID: 26039764
48. Ferrante Di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ. 2012;344:e686. doi: 10.1136/bmj.e686 PMID: 22354600
49. Schäfer HH, Filser L, Rohr UP, Laubender RP, Dieterle T, Maitland R, et al. Medical value as a new strategy to increase corporate viability: Market chances and limitations in the diagnostic industry. J Entrepren Organiz Manag. 2015;4:131.
50. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142:786-791. PMID: 15867411
51. Mair J, Smidt J, Lechleitner P, Dienstl F, Puschendorf B. Rapid accurate diagnosis of acute myocardial infarction in patients with non-traumatic chest pain within 1 h of admission. Coron Artery Dis. 1995;6:539-545. PMID: 7582192
52. Timp JF, Lijfering WM, Flinterman LE, Van Hylckama Vlieg A, Le Cessie S, Rosendaal FR, et al. Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study. J Thromb Haemost. 2015;13:1823-1832. doi: 10.1111/jth.13113 PMID: 26270389
53. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10(14 Suppl):S451-S458; discussion S458-S461. PMID: 15696909
54. Knottnerus JA, Buntinx F. The evidence base of clinical diagnosis: Theory and methods of diagnostic research. Oxford, UK: BMJ Books; 2011.